IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type i IFN-Dependent Inflammatory Disease

Journal of Immunology

Volumn 193, Issue 6, 2014, Pages 2733-2742

  Srivastava, Shivani ^a,b   Koch, Lisa K ^a,b   Campbell, Daniel J ^a,b  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; EXONUCLEASE; INTERFERON; TRANSCRIPTION FACTOR FOXP3; TREX1 EXONUCLEASE; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; EXODEOXYRIBONUCLEASE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; PHOSPHOPROTEIN; THREE PRIME REPAIR EXONUCLEASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL EXPANSION; CELL HYPERPLASIA; CELL INFILTRATION; CELL POPULATION; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; EFFECTOR CELL; GOBLET CELL; HISTOLOGY; IMMUNE DYSREGULATION; INFLAMMATORY DISEASE; INTESTINE CRYPT; INTESTINE ULCER; LAMINA PROPRIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; WEIGHT REDUCTION; ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CELLS, CULTURED; COLITIS; EXODEOXYRIBONUCLEASES; FORKHEAD TRANSCRIPTION FACTORS; INFLAMMATION; INTERFERON TYPE I; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHOPROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84907087667     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401039     Document Type: Article

References (46)

1. Baccala, R., D. H. Kono, and A. N. Theofilopoulos. 2005. Interferons as pathogenic effectors in autoimmunity. Immunol. Rev. 204: 9-26
2. Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M . Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100: 2610-2615.
3. Bennett L.,A. K. Palucka,E. Arce,V. Cantrell,J. Borvak,J. Banchereau,V. Pascual, 2003, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med, 197, 711-723.
4. M oser, K. L., J. A. Kelly, C. J. Lessard, and J. B. Harley. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10: 373-379
5. Gota, C., and L. Calabrese. 2003. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 36: 511-518
6. Mavrogiannis, C., I. S. Papanikolaou, I. S. Elefsiniotis, D. I. Psilopoulos, A. Karameris, and G. Karvountzis. 2001. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. J. Hepatol. 34: 964-965
7. Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23: 307-336
8. Srivastava, S., M. A. Koch, M. Pepper, and D. J. Campbell. 2014. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211: 961-974
9. Biron, C. A. 2001. Interferons alpha and beta as immune regulators-A new look. Immunity 14: 661-664
10. Luft, T., K. C. Pang, E. Thomas, P. Hertzog, D. N. Hart, J. Trapani, and J. Cebon. 1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161: 1947-1953
11. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 2005. Type I interferons act directly on CD8 T cells to allow c lonal expansion and memory formation in response to viral infection. J. Exp. Med. 202: 637-650
12. Havenar-Daughton, C., G. A. Kolumam, and K. Murali-Krishna. 2006. Cutting edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176: 3315-3319
13. Gil, M. P., R. Salomon, J. Louten, and C. A. Biron. 2006. Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. Blood 107: 987-993
14. Gil, M. P., M. J. Y. Ploquin, W. T. Watford, S.-H. Lee, K. Kim, X. Wang, Y. Kanno, J. J. O'Shea, and C. A. Biron. 2012. Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for fu nction. Blood 120: 3718-3728
15. Wilson, E. B., D. H. Yamada, H. Elsaesser, J. Herskovitz, J. Deng, G. Cheng, B. J. Aronow, C. L. Karp, and D. G. Brooks. 2013. Blockade of chronic typ e I interferon signaling to control persistent LCMV infection. Science 340: 202-207
16. Teijaro, J. R, C. Ng, A. M. Lee, B. M. Sullivan, K. C. Sheehan, M. Welch, R. D. Schreiber, J. C. de la Torre, and M. B. Oldstone. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340: 207-211
17. Longhi, M. P., C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, A. M. Salazar, M. Colonna, and R. M. Steinman. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206: 1589-1602
18. Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, et al. 2011. Type I interferon is sel ectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208: 1989- 2003
19. Yan, B., S. Ye, G. Chen, M. Kuang, N. Shen, and S. Chen. 2008. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 58: 801-812
20. Martinez, J., X. Huang, and Y. Yang. 2008. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J. Immunol. 180: 1592-1597
21. Goossens, P., M. J. J. Gijbels, A. Zernecke, W. Eijgelaar, M. N. Vergouwe, I. van der Made, J. Vanderlocht, L. Beckers, W. A. Buurman, M. J. A. P. Daemen, et al. 2010. Myeloid type I interferon signaling pr omotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab. 12: 142-153
22. Lefrancois, L., and N. Lycke. 2001. Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells. Curr. Protoc. Immunol. Chapter 3: Unit 3.19
23. Goodman, T., and L. Lefrancois. 1989. Intraepithelial lymphocytes. Anatomical site, not T cell receptor form, dictates phenotype and function. J. Exp. Med. 170: 1569-1581.
24. Asseman C.,S. Mauze,M.W. Leach,R.L. Coffman,F. Powrie, 1999, An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation,J. Exp. Med, 190, 995-1004.
25. Yang, Y. G., T. Lindahl, and D. E. Barnes. 2007. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131: 873-886
26. Stetson, D. B., J. S. Ko, T. Heidmann, and R. Medzhitov. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587-598
27. Morita, M., G. Stamp, P. Robins, A. Dulic, I. Rosewell, G. Hrivnak, G. Daly, T. Lindahl, and D. E. Barnes. 2004. Gene-targeted mice lacking the Trex1 (DNase III) 39-.59 DNA exonuclease develop in flammatory myocarditis. Mol. Cell. Biol. 24: 6719-6727
28. Rice, G., W. G. Newman, J. Dean, T. Patrick, R. Parmar, K. Flintoff, P. Robins, S. Harvey, T. Hollis, A. O'Hara, et al. 2007. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80: 811-815
29. Gall, A., P. Treuting, K. B. Elkon, Y.-M. Loo, M. Gale, Jr., G. N. Barber, and D. B. Stetson. 2012. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36: 120-131
30. Read, S., R. Greenwald, A. Izcue, N. Robinson, D. Mandelbrot, L. Francisco, A. H. Sharpe, and F. Powrie. 2006. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J. Immunol. 177: 4376-4383.
31. Mottet, C., H. H. Uhlig, and F. Powrie. 2003. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 170: 3939-3943
32. Kole, A., J . He, A. Rivollier, D. D. Silveira, K. Kitamura, K. J. Maloy, and B. L. Kelsall. 2013. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J. Immunol. 191: 2771-2779
33. Sun, S., X. Zhang, D. F. Tough, and J. Sprent. 1998. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188: 2335-2342
34. Shiow, L. R., D. B. Rosen, N. Brdicková, Y. Xu, J. An, L. L. Lanier, J. G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lympho id organs. Nature 440: 540-544
35. Golding, A., A. Rosen, M. Petri, E. Akhter, and F. Andrade. 2010. Interferonalpha regulates the dynamic balance between human activated regulatory and eff ector T cells: implications for antiviral and autoimmune responses. Immunology 131: 107-117
36. Mozzillo, N., and P. Ascierto. 2012. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients. Clin. Exp. Metastasis 29: 801-805
37. Namdar, A., B. Nikbin, M. Ghabaee, A. Bayati, and M. Izad. 2010. Effect of IFN-beta therapy on the frequency and functi on of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J. Neuroimmunol. 218: 120-124
38. Pace, L., S. Vitale, B. Dettori, C. Palombi, V. La Sorsa, F. Belardelli, E. Proietti, and G. Doria. 2010. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184: 5969-5979
39. Riley, C. H., M. K. Jensen, M. K. Brimnes, H. C. Hasselbalch, O. W. Bjerrum, P. T. Straten, and I. M. Svane. 2011. Increase in circulating CD4-CD25-Foxp3- T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-a. Blood 118: 2170-2173
40. Lee, S. E., X. Li, J. C. Kim, J. Lee, J. M. González-Navajas, S. H. Hong, I. K. Park, J. H. Rhee, and E. Raz. 2012. Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. 143: 145-154
41. Pierson, W., B. Cauwe, A. Policheni, S. M. Schlenner, D. Franckaert, J. Berges, S. Humblet-Baron, S. Schö nefeldt, M. J. Herold, D. Hildeman, et al. 2013. Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3? regulatory T cells. Nat. Immunol. 14: 959-965
42. Tischner, D., I. Gaggl, I. Peschel, M. Kaufmann, S. Tuzlak, M. Drach, N. Thuille, A. Villunger, and G. Jan Wiegers. 2012. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg development and limits their functionality in mice. J. Autoimmun. 38: 59-69
43. Powrie, F., M. W. Leach, S. Mauze, S. Menon, L. B. Caddle, and R. L. Coffman. 1994. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1: 553-562.
44. Korn, T., J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T. R. Petersen, B. T. Bäckströ m, R. A. Sobel, K. W. Wucherpfennig, T. B. Strom, et al. 2007. Myelin-specific regulatory T cell s accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13: 423-431
45. Schenten, D., S. A. Nish, S. Yu, X. Yan, H. K. Lee, I. Brodsky, L. Pasman, B. Yordy, F. T. Wunderlich, J. C. Br€ uning, et al. 2014. Signaling through the adaptor molecule MyD88 in CD4(+) T cells is required to overcome suppression by regulatory T cells. 40: 78-90.
46. Goldstein D..J. Laszlo, 1986, Interferon therapy in cancer: from imaginon to interferon, Cancer Res, 46, 4315-4329.